SanBio Co., Ltd. engages in the development, production and sale of regenerative cells medicines. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 29 full-time employees. The company went IPO on 2015-04-08. The firm has the research and development base in the United States and conducts research, development, manufacture and sale of regenerative cell medicines in Japan. The firm aims to sell therapeutic agents for diseases with high unmet medical needs, mainly in diseases of the central nervous system. The company is involved in the manufacture, development, non-clinical studies, clinical trials of technologies introduced from research institutes such as universities. The firm has five regenerative cell drugs, including the main product candidate SB623 (nerve regenerative cells), SB618 (function-enhancing type & Mesenchymal stem cells), SB308 (muscle stem cells), MSC1 (mesenchymal stem cells), and MSC2 (mesenchymal stem cells).
Follow-Up Questions
Who is the CEO of SanBio Co Ltd?
Mr. Keita Mori is the President of SanBio Co Ltd, joining the firm since 2013.
What is the price performance of SNBIF stock?
The current price of SNBIF is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for SanBio Co Ltd?
SanBio Co Ltd belongs to Biotechnology industry and the sector is Health Care
What is SanBio Co Ltd market cap?
SanBio Co Ltd's current market cap is $0
Is SanBio Co Ltd a buy, sell, or hold?
According to wall street analysts, 6 analysts have made analyst ratings for SanBio Co Ltd, including 0 strong buy, 0 buy, 4 hold, 3 sell, and 0 strong sell
